Read more

January 30, 2023
2 min read
Save

More frequent CT scans not linked to better outcomes after lung cancer surgery

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Frequent postoperative surveillance imaging after lung cancer resection did not improve outcomes for patients with stage I non-small cell lung cancer, according to data published in Journal of the National Cancer Institute.

Guidelines from National Comprehensive Cancer Network, ASCO and other organizations recommend chest CT scans every 6 months for the first 2 to 3 years following lung resection. However, fewer scans could streamline care, lower costs and reduce anxiety associated with more frequent surveillance, researchers wrote.

Pull quote from Brendan T. Heiden, MD, MPHS

“Our study builds on a growing body of evidence that more frequent surveillance does not improve outcomes in early-stage lung cancer,” Brendan T. Heiden, MD, MPHS, surgical resident and research fellow at Washington University School of Medicine in St. Louis, told Healio. “While this may be a somewhat surprising finding, similar observations have been found in other malignancies, including colon cancer. Although the potential benefits of more frequent surveillance may be intuitive — ie, earlier detection, more aggressive treatment, etc. — the potential harms of overly aggressive surveillance must also be considered.”

Background

Surgical resection is standard treatment for patients with early-stage NSCLC. However, approximately 20% to 50% of patients develop recurrence within 5 years. Consequently, surveillance has become a crucial part of postoperative care.

However, prior studies suggested more frequent postoperative surveillance imaging with CT may not improve outcomes for patients who undergo resection for stage I NSCLC.

Heiden and colleagues aimed to assess the relationship between surveillance frequency and RFS and OS.

Methodology

Researchers performed a retrospective cohort study of veterans with pathologic stage I NSCLC who underwent surgery between 2006 and 2016.

The cohort included 6,171 patients (median age, 67.5 years; 96.3% male) who underwent low-frequency surveillance (< 2 scans per year/every 6 to 12 months; n = 3,047) or high-frequency surveillance ( 2 scans per year/every 3 to 6 months; n = 3,124).

Researchers excluded patients who received more than four scans per year, as well as those who received only one scan over a 2-year period.

Results

After median follow-up of 7.3 years (range, 3.4-12.5), researchers determined 1,360 (22%) patients developed recurrence.

Results showed no association between high-frequency surveillance and longer RFS (adjusted HR = 0.93; 95% CI, 0.83-1.04) or OS (adjusted HR = 1.04; 95% CI, 0.96-1.12).

Factors associated with high-frequency surveillance included being a former smoker (vs. current, adjusted OR [aOR] = 1.18; 95% CI, 1.05-1.33), receiving a wedge resection (vs. lobectomy, aOR = 1.21; 95% CI, 1.05-1.39) and having follow-up with an oncologist (aOR = 1.58; 95% CI, 1.42-1.77).

Black individuals received low-frequency surveillance at a greater rate than white individuals (aOR = 0.64; 95% CI, 0.54-0.75).

Researchers reported median OS of 65.7 months (95% CI, 64-67.4) in the low-frequency group and 64.4 months (95% CI, 62.6-66.1) in the high-frequency group.

“These findings — in agreement with a growing body of other studies — suggest that post-resection lung cancer surveillance should occur at least annually, but that no clear benefit exists for more than semiannual surveillance within the first 2years after surgery for stage I disease,” Heiden told Healio.

Next steps

Researchers did not observe an association between more aggressive surveillance and improved cancer-specific outcomes, pointing toward the potential to adjust guidelines.

“[Although] additional prospective studies are needed to confirm these observations, future lung cancer treatment guidelines should consider less frequent surveillance — especially [for] low-risk groups, such as patients with early-stage disease,” Heiden told Healio.

For more information:

Brendan T. Heiden, MD, MPHS, can be reached at Washington University School of Medicine in St. Louis, 660 S. Euclid Ave., Campus Box 8234, St. Louis, MO 63110; email: bheiden@wustl.edu.